Actualités sur Medicale

Astellas Pharma Europe Limited

Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...

Novo Nordisk

Tresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Orlando, Florida (ots/PRNewswire) - Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE) study comparing the ...

Novo Nordisk

Ozempic® Provided Greater Weight Reductions for Adults With a Baseline BMI >=25kg/m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

Orlando, Florida (ots/PRNewswire) - Poster Presentation #1083-P Ozempic® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults ...

Novo Nordisk

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

Orlando, Florida (ots/PRNewswire) - Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated the efficacy and safety of ...

Novo Nordisk

Significant Blood Sugar Improvement With Xultophy® Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications

Bagsværd, Denmark (ots/PRNewswire) - Oral Presentation #127-OR Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy® (insulin degludec and liraglutide ...

Merck Healthcare Germany GmbH

Merck to Present Data on Mavenclad® and Rebif® in Relapsing Forms of Multiple Sclerosis at EAN

Darmstadt, Germany (ots/PRNewswire) - - 14 abstracts to be presented, further characterizing the complementary profiles of Mavenclad (cladribine tablets)and Rebif (interferon beta-1a) Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 4th Congress of ...

OxThera AB

OxThera Announces the Appointment of Dr Alain Munoz to its Board of Directors

Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the appointment of Dr Alain Munoz to its board of directors. "It is my pleasure to welcome Alain to the board of Oxthera," said Dr. Georges Gemayel, Chairman of Oxthera. ...

icotec AG

2

icotec AG Received FDA Clearance to Market BlackArmor® Carbon/PEEK Interbody Cages

Grünenthal Gruppe

Grünenthal Initiates Pivotal Phase III Trials in Complex Regional Pain Syndrome

Aachen, Germany (ots) - Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome (CRPS). These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. ...

Janssen Pharmaceutica

Janssen to Showcase New Data Across Broad Rheumatology Portfolio and Immunology Pipeline at EULAR 2018

Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE ONLY The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that ten company-sponsored abstracts will be presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, Netherlands being held on 13-16 June. Data from the ...

UCB Pharma

New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018) Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory Diseases

Brussels (ots/PRNewswire) - - Late-breaking oral presentation on bimekizumab shows significant potential for treating ankylosing spondylitis (AS) - Oral presentation on CIMZIA® (certolizumab pegol) pregnancy outcomes shows no increased risk of major congenital malformations compared to the general population nor an ...

IMI-PainCare

IMI-PainCare: Public-private partnership tackles major challenges in the care of pain patients

Aachen (ots) - To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project "IMI-PainCare - Improving the care of patients suffering from acute or ...

Merck Healthcare Germany GmbH

Merck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018

Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - M7824 is an investigational immunotherapy that is designed to bring together ...

Hitachi Medical Systems Europe Holding AG

Hitachi Medical Systems Europe wins the contract to supply 6 ultrasound systems in the UK helping to improve prostate cancer diagnosis ...

Zug, Switzerland (ots) - Hitachi Medical Systems Europe wins the contract to supply 6 ultrasound systems in the UK helping to improve prostate cancer diagnosis as part of the innovative RAPID programme at three major hospitals across South West London The new RAPID (Rapid Assessment Prostate Imaging and Diagnosis) ...

Merck Healthcare Germany GmbH

Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)

Chicago (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Two-year follow-up data on meaningful durable response, overall survival (OS) and progression-free survival (PFS) to be presented in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin cancer Merck and ...

Merck Healthcare Germany GmbH

Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - Data from an ongoing Phase II tepotinib study show anti-tumor clinical activity in ...

Takeda Pharmaceutical Company Limited

Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

Osaka, Japan (ots/PRNewswire) - Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week (DDW) 2018 meeting Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced a new analysis of ...

Galderma

Galderma Global Study Reveals True Burden of Rosacea and Encourages Healthcare Professionals to Look 'Beyond the visible'

Lausanne, Switzerland (ots/PRNewswire) - Galderma today released the findings of a global survey highlighting the need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea and ways in which they can work together to achieve 'clear' (IGA 0) skin*. In the form of ...

Merck Healthcare Germany GmbH

World MS Day 2018: Call for Greater Curiosity to Drive Understanding of the Disease and Future Innovation

Darmstadt, Germany (ots/PRNewswire) - - Launch of #MSInsideOut campaign, aimed at providing a deeper understanding of multiple sclerosis (MS) - Donation to the MS International Federation (MSIF)* of up to EUR20,000 - Shift.ms to Executive Produce a documentary to highlight stories and unique perspectives within the ...

European Society for Medical Oncology (ESMO)

ESMO emphasises importance of cancer on global health agenda at WHA

Novo Nordisk

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda®

Vienna (ots/PRNewswire) - People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European Congress on Obesity (ECO 2018) in Vienna, Austria and the 23rd Annual International Meeting of the ...

UCB Pharma

UCB Joins with ILAE and IBE to Encourage World Health Assembly Members to Continue Recognition of Epilepsy as Global Health Priority

Brussels and Geneva (ots/PRNewswire) - - Significant gaps in epilepsy management, awareness, and effective treatment access continue around the world - Groups are launching a call to action for public and private engagement to join the fight against Epilepsy through a sustained commitment towards the Resolution on ...

Novo Nordisk

Head-to-Head Trial Shows Refixia® Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Glasgow, Scotland (ots/PRNewswire) - Adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed a longer half-life for ...

Novo Nordisk

NovoEight® Maintains Potency When Stored at 40ºC Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

Glasgow, Scotland (ots/PRNewswire) - A new long term stability study has shown that haemophilia A treatment NovoEight® (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow, UK. Treatment storage issues, ...

Daiichi Sankyo Europe GmbH

LIXIANA® (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018

Munich (ots/PRNewswire) - - Sub-analysis presented from ENGAGE AF-TIMI 48, the longest single comparative global trial of a non-vitamin K oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date - Results showed a reduction in both spontaneous and traumatic intracranial haemorrhage ...

Kyowa Kirin International PLC

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)

Novato, California, Tokyo and London (ots/PRNewswire) - Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy at 40 Weeks Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel ...

Merck Healthcare Germany GmbH

Merck Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ASCO Abstract # ERBITUX® (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814 (DNA-PK): 2518 M7824 (TGF-ß ...

Sequana Medical AG

Sequana Medical announces inclusion of alfapump® in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites

Zurich (ots) - Sequana Medical AG ("Sequana Medical"), a commercial stage medical device company and an innovator in the management of liver disease & malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018. First, ...

BioLamina AB

BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions

Stockholm (ots/PRNewswire) - BioLamina and collaborators have partnered with Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, allowing Novo Nordisk to develop novel stem cell based therapies based on Biolaminins, human recombinant laminin cell culture matrices, developed and produced ...

Accuray Europe

Accuray Unveils New Company Website Reflecting Industry-Leading Patient-First Cancer Treatment Innovation and Care

Sunnyvale, California (ots/PRNewswire) - Accuray Incorporated (Nasdaq: ARAY) announced today the unveiling of a new corporate website that reflects the company's evolution and leadership in patient-first cancer treatment innovations. The fully redesigned, modern site puts critical disease and treatment information ...